Novavax: All Eyes on Upcoming FDA Advisory Meeting
yahoo.com
news
2022-05-28 23:36:58

It's difficult for most stocks to make any headway in 2022. Inflation, rising interest rates and Russia's ongoing war on Ukraine have dragged down even those with minimal exposure to the macro headwinds.

For Novavax (NVAX), these worries have been amplified by other considerations. First, there is the prospect of dwindling global demand for Covid-19 vaccines, what with the virus on the backfoot in many parts of the world and there being an oversupply in selected regions. Secondly, in the U.S. at least, the company has yet to get its vaccine NVX-CoV2373 across the finish line.
